Stay updated on CX-072 Dose-finding Clinical Trial

Sign up to get notified when there's something new on the CX-072 Dose-finding Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CX-072 Dose-finding Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:20:51.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the information related to the first-in-human study of CX-072, a Probody™ therapeutic directed against PD-L1, for patients with advanced or recurrent solid tumors or lymphomas.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:32.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the need for a histologically confirmed diagnosis of metastatic or advanced unresectable tumors and the agreement to provide mandatory archival tissue. Previously, no specific information was provided in this section.
    Difference
    18%
    Check dated 2024-05-22T21:24:10.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:25:14.000Z thumbnail image

Stay in the know with updates to CX-072 Dose-finding Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CX-072 Dose-finding Clinical Trial page.